Comparative Pharmacology
Head-to-head clinical analysis: CRYSVITA versus KEVZARA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CRYSVITA versus KEVZARA.
CRYSVITA vs KEVZARA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fibroblast growth factor 23 (FGF23) inhibitor; increases renal phosphate reabsorption and 1,25-dihydroxyvitamin D production by blocking FGF23 activity.
Interleukin-6 (IL-6) receptor antagonist; sarilumab binds specifically to both soluble and membrane-bound IL-6 receptors, inhibiting IL-6-mediated signaling through gp130 and STAT3.
1 mg/kg subcutaneously once monthly; maximum dose 90 mg. Administer at a fixed date each month.
200 mg subcutaneously once weekly.
None Documented
None Documented
16.4 days (terminal elimination half-life); supports monthly subcutaneous dosing.
Terminal elimination half-life ~21-22 days, supporting subcutaneous dosing every 2 weeks.
Renal (minimal, as intact antibody); catabolized into small peptides and amino acids; no biliary/fecal elimination of intact drug.
Primarily eliminated via reticuloendothelial system catabolism. No significant renal or biliary excretion; <1% excreted unchanged in urine or feces.
Category C
Category C
Monoclonal Antibody
Monoclonal Antibody, IL-6 Receptor Antagonist